Table 1 Comparison of Tirzepatide vs Semaglutide for ocular outcomes

From: Comparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity

 

Tirzepatide

Semaglutide

Risk Difference (95% CI)

ARD (%)

HR-Based RRR (%)

HR (95%CI)

P-Value

E-value For HR

E-value for lower CI of HR

Cataract

32/24,377 (0.1)

43/24,385 (0.2)

−0.0005 (−0.0011 to 0.0002)

0.05

N/A

0.87 (0.55, 1.37)

0.540

N/A

N/A

Oculomotor binocular dysfunction

44/23,568 (0.2)

47/23,789 (0.2)

−0.0001 (−0.0009 to 0.0007)

0.01

N/A

1.09 (0.72, 1.64)

0.693

N/A

N/A

Visual issues blindness

61/23,218 (0.3)

98/23,413 (0.4)

−0.0016 (−0.0026 to −0.0005)

0.16

N/A

0.74 (0.54, 1.03)

0.070

N/A

N/A

Dry eye disease

29/24,367 (0.1)

36/24,464 (0.1)

−0.0003 (−0.0009 to 0.0004)

0.03

N/A

0.96 (0.59, 1.56)

0.863

N/A

N/A

Ametropic accommodative dysfunction

44/23,662 (0.2)

47/23,880 (0.2)

−0.0001 (−0.0009 to 0.0007)

0.01

N/A

1.09 (0.72, 1.64)

0.691

N/A

N/A

Visual disturbances

53/23,419 (0.2)

86/23,606 (0.4)

−0.0014 (−0.0024 to −0.0004)

0.14

N/A

0.73 (0.52, 1.03)

0.076

N/A

N/A

NCOs

459/18,494 (2.5)

537/18,484 (2.9)

−0.0042 (−0.0075 to −0.0009)

0.42

N/A

0.96 (0.85, 1.09)

0.575

N/A

N/A

  1. Percentages of individual numbers are rounded to one decimal place following conventional rounding rules.
  2. ARD absolute risk difference, RRR relative risk reduction, NCOs negative control outcomes.
Back to article page